BVF Inc. IL Cuts Position in Monte Rosa Therapeutics, Inc. $GLUE

BVF Inc. IL trimmed its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 32.2% in the fourth quarter, HoldingsChannel reports. The fund owned 3,835,886 shares of the company’s stock after selling 1,824,246 shares during the period. Monte Rosa Therapeutics makes up 2.0% of BVF Inc. IL’s investment portfolio, making the stock its 17th biggest position. BVF Inc. IL owned approximately 0.06% of Monte Rosa Therapeutics worth $60,147,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its holdings in shares of Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after acquiring an additional 776 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of Monte Rosa Therapeutics by 8.3% in the 3rd quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock worth $82,000 after acquiring an additional 848 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Monte Rosa Therapeutics by 11.8% in the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock worth $178,000 after acquiring an additional 1,199 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 7.5% in the 4th quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock worth $411,000 after acquiring an additional 1,831 shares during the last quarter. 79.96% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Philip Nickson sold 5,845 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $17.69, for a total value of $103,398.05. Following the sale, the insider directly owned 55,000 shares of the company’s stock, valued at $972,950. This trade represents a 9.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $20.00, for a total value of $43,500.00. Following the completion of the sale, the chief operating officer directly owned 62,371 shares in the company, valued at $1,247,420. The trade was a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.40% of the stock is owned by company insiders.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $18.41 on Thursday. The stock has a market capitalization of $1.56 billion, a PE ratio of -12.44 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77. The business’s 50-day moving average is $18.60 and its 200 day moving average is $18.47.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Guggenheim decreased their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. JPMorgan Chase & Co. lifted their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.